Breaking Down IDEAYA Biosciences, Inc. (IDYA) Financial Health: Key Insights for Investors

Breaking Down IDEAYA Biosciences, Inc. (IDYA) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

IDEAYA Biosciences, Inc. (IDYA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding IDEAYA Biosciences, Inc. (IDYA) Revenue Streams

Revenue Analysis

IDEAYA Biosciences, Inc. reported total revenue of $76.1 million for the fiscal year 2023, with a detailed breakdown of revenue streams:

Revenue Source Amount ($) Percentage
Collaboration Revenues $64.3 million 84.5%
Research Grants $11.8 million 15.5%

Year-over-year revenue growth details:

  • 2022 Total Revenue: $53.2 million
  • 2023 Total Revenue: $76.1 million
  • Revenue Growth Rate: 43.2%

Key revenue insights for 2023:

  • Collaboration revenue increased from $42.5 million in 2022 to $64.3 million in 2023
  • Research grant income grew from $10.7 million to $11.8 million
Business Segment 2022 Revenue 2023 Revenue Growth
Precision Oncology $38.6 million $55.4 million 43.5%
DNA Damage Response $14.6 million $20.7 million 41.8%



A Deep Dive into IDEAYA Biosciences, Inc. (IDYA) Profitability

Profitability Metrics Analysis

Financial performance metrics reveal critical insights into the company's operational efficiency and revenue generation capabilities.

Profitability Metric 2023 Value 2022 Value
Gross Profit Margin 0% 0%
Operating Margin -74.8% -80.5%
Net Profit Margin -76.6% -83.3%

Key Profitability Insights

  • Research and development expenses: $154.6 million in 2023
  • Total operating expenses: $178.8 million in 2023
  • Net loss: $117.4 million for fiscal year 2023

Operational Efficiency Metrics

Efficiency Indicator 2023 Performance
Cash Used in Operations $137.4 million
Cash and Investments $331.1 million



Debt vs. Equity: How IDEAYA Biosciences, Inc. (IDYA) Finances Its Growth

Debt vs. Equity Structure Analysis

IDEAYA Biosciences, Inc. financial structure reveals a nuanced approach to capital management as of the latest reporting period.

Debt Overview

Total long-term debt as of December 31, 2023: $95.4 million

Debt-to-Equity Ratio

Metric Value
Total Debt $95.4 million
Shareholders' Equity $318.7 million
Debt-to-Equity Ratio 0.30

Financing Characteristics

  • Convertible Notes: $86.3 million
  • Credit Facility Limit: $50 million
  • Current Borrowing: $0 drawn

Equity Financing Details

Equity Raised in 2023: $127.6 million through public offering

Financing Type Amount
Common Stock Offering $127.6 million
Warrant Exercises $12.4 million



Assessing IDEAYA Biosciences, Inc. (IDYA) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Metric Value
Current Ratio 2.15
Quick Ratio 1.87
Working Capital $156.4 million

Cash flow statement analysis reveals the following key trends:

Cash Flow Category Amount
Operating Cash Flow $-42.3 million
Investing Cash Flow $-23.7 million
Financing Cash Flow $68.5 million

Key liquidity strengths include:

  • Cash and cash equivalents of $214.6 million
  • Marketable securities valued at $89.2 million
  • Minimal short-term debt obligations

Potential liquidity considerations:

  • Negative operating cash flow of $42.3 million
  • Continued research and development expenditures
  • Ongoing clinical trial investments

The company maintains a solid liquidity position with $303.8 million in total liquid assets, providing substantial financial flexibility for operational and strategic initiatives.




Is IDEAYA Biosciences, Inc. (IDYA) Overvalued or Undervalued?

Valuation Analysis

As of February 2024, the financial metrics for the company reveal critical valuation insights:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -14.52
Price-to-Book (P/B) Ratio 3.62
Enterprise Value/EBITDA -15.73
Current Stock Price $7.85

Stock price performance details:

  • 52-week low: $4.12
  • 52-week high: $10.56
  • Price volatility: 48.3%

Analyst recommendations breakdown:

Recommendation Percentage
Buy 62%
Hold 31%
Sell 7%

Additional key valuation indicators:

  • Market Capitalization: $341.2 million
  • Dividend Yield: 0%
  • Price/Sales Ratio: 8.47



Key Risks Facing IDEAYA Biosciences, Inc. (IDYA)

Risk Factors for the Company

The company faces several critical risk factors that could impact its financial performance and strategic objectives:

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $101.4 million cash and cash equivalents as of Q3 2023
Research Funding Dependency on External Funding Potential funding gaps in clinical development

Operational Risks

  • Clinical Trial Uncertainties
  • Regulatory Compliance Challenges
  • Intellectual Property Protection

Market and Competitive Risks

Key market risks include:

  • Intense competition in precision oncology segment
  • Rapid technological changes in biotechnology
  • Potential market entry barriers

Regulatory Risk Assessment

Regulatory Area Risk Level Potential Consequence
FDA Approval Process High Potential delays in drug development
Clinical Trial Compliance Medium Potential regulatory penalties

Research and Development Risks

R&D risks include:

  • High failure rates in drug development
  • Complex scientific challenges
  • Significant investment requirements

Financial Performance Risks

Financial risk indicators:

  • Net loss of $62.4 million for the nine months ended September 30, 2023
  • Ongoing research and development expenses
  • Limited revenue generation



Future Growth Prospects for IDEAYA Biosciences, Inc. (IDYA)

Growth Opportunities

IDEAYA Biosciences demonstrates significant potential for future growth across multiple strategic dimensions.

Key Growth Drivers

  • Oncology pipeline with 4 clinical-stage precision medicine programs
  • Focus on synthetic lethality and DNA damage response therapeutic areas
  • Promising targeted cancer therapies in development

Financial Growth Projections

Metric 2023 Value 2024 Projected
Research & Development Expenses $90.2 million $95-100 million
Cash and Investments $283.1 million $270-290 million

Strategic Partnerships

  • Collaboration with GSK for PARP inhibitor programs
  • Multiple ongoing strategic research agreements
  • Potential milestone payments from existing partnerships estimated at $50-75 million

Competitive Advantages

  • Proprietary synthetic lethality discovery platform
  • Precision medicine approach targeting specific genetic mutations
  • Strong intellectual property portfolio with 15+ patent families

DCF model

IDEAYA Biosciences, Inc. (IDYA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.